Santaris, Miragen Form miRNA Drug Alliance | GenomeWeb

Santaris Pharma and Miragen Therapeutics announced this week that they have formed a strategic alliance to develop microRNA-targeting drugs for cardiovascular disease.

Under the deal, Miragen will use Santaris' proprietary locked nucleic acid technology to develop single-stranded RNAs against its own miRNA targets related to cardiovascular disease. In exchange, Santaris received an undisclosed minority interest in Miragen, and is eligible to receive milestones and royalties related to the achievement of certain development and regulatory goals.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.